TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17853748

Group type: EXPERIMENTAL
Intervention: Combination group (Jiaji EA plus laser needle-knife)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Laser needle-knife group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Jiaji EA group
Number of subjects: 120
Study: 15120821

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing
Number of subjects: 2010

Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Overall stroke rate
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Clinical characteristics (prior stroke, race, hypertension, etc.)
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation after implantation
Number of subjects: 2010
Study: 11281047

Group type: EXPERIMENTAL
Intervention: 100 micrograms.kg‐1 rocuronium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 150 micrograms.kg‐1 rocuronium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 300 micrograms.kg‐1 rocuronium
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9159735

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8267111

Group type: EXPERIMENTAL
Intervention: Monosialoganglioside (GM1) 100 mg/day i.m. for 6 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 12
Study: 3115131

Group type: EXPERIMENTAL
Intervention: 1 mg/kg b.w. flecainide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 20
Study: 31970383

Group type: COMPARATOR
Intervention: High walking ability group (n=60)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low walking ability group (n=60)
Number of subjects: 120
Study: 29980235

Group type: EXPERIMENTAL
Intervention: KEIGAAF intervention
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 11
Study: 27056702

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) after RME (n=10)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (RME alone, n=4)
Number of subjects: 14
Study: 25420434

Group type: EXPERIMENTAL
Intervention: VIA
Number of subjects: 259

Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 259
Study: 23616511

Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation (9 months of weekly play sessions at home)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Iron treatment (30 mg daily for 6 months)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Psychosocial stimulation
Number of subjects: 434
Study: 21039349

Group type: EXPERIMENTAL
Intervention: Perisciatic infusion of ropivacaine 2 mg/ml at a rate of 5 ml/h
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Perisciatic infusion of ropivacaine 2 mg/ml at a rate of 8 ml/h
Number of subjects: 40
Study: 18498923

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study: 16617103

Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 (5.0 log(10) PFU)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 (3.0 log(10) PFU)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: YF‐VAX
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 14635973

Group type: EXPERIMENTAL
Intervention: Tetracaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 10642705

Group type: EXPERIMENTAL
Intervention: Eversion carotid endarterectomy (CEA)
Number of subjects: 1353

Group type: COMPARATOR
Intervention: Standard carotid endarterectomy (CEA)
Number of subjects: 1353
Study: 9048325

Group type: EXPERIMENTAL
Intervention: Goniometric measurement by experienced testers (>=10 years experience)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Goniometric measurement by inexperienced testers (physical therapy students)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Visual estimation by experienced testers (>=10 years experience)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Visual estimation by inexperienced testers (physical therapy students)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Goniometric measurement (intertester reliability)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Visual estimation (intertester reliability)
Number of subjects: 10
Study: 8393273

Group type: EXPERIMENTAL
Intervention: Higher dose intensity regimens
Number of subjects: 122

Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, and vincristine (control group)
Number of subjects: 122
Study: 3554461

Group type: EXPERIMENTAL
Intervention: Clindamycin + Gentamycin (C + G)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Metronidazole + Gentamycin (M + G)
Number of subjects: 45
Study: 30189232

Group type: EXPERIMENTAL
Intervention: Thought record condition
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 100
Study: 26204351

Group type: EXPERIMENTAL
Intervention: Daily foetal movement counting from 28 weeks' gestation (n = 100)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Standard Iranian antenatal care (n = 108)
Number of subjects: 208
Study: 23937186

Group type: EXPERIMENTAL
Intervention: Wise feedback (treatment condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attributional retraining (Study 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 21716318

Group type: EXPERIMENTAL
Intervention: Percutaneous renal angioplasty and stenting (PTRAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 0
Study: 21992833

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional medical management
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) and Conventional medical management
Number of subjects: 100
Study: 18703471

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 4570

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 4570
Study: 15615822

Group type: EXPERIMENTAL
Intervention: Combined ramipril at 5 mg/d and valsartan at 80 mg/d with increased furosemide dosage
Number of subjects: 18

Group type: COMPARATOR
Intervention: Valsartan at 160 mg/d
Number of subjects: 18

Group type: COMPARATOR
Intervention: Combined ramipril at 5 mg/d and valsartan at 80 mg/d
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ramipril at 10 mg/d
Number of subjects: 18
Study: 12911138

Group type: EXPERIMENTAL
Intervention: Incremental workload bicycle exercise in HSP patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 10
Study: 9605723

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Withholding treatment (no AEDs)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Subsequent treatment regimens after 3 failures
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: AEDs in children with longest remission < 6 months
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Overall outcome of epilepsy treatment
Number of subjects: 494
Study: 7798008

Group type: EXPERIMENTAL
Intervention: Lateral soft tissue radiographs interpretation
Number of subjects: 60
Study: 2660559

Group type: EXPERIMENTAL
Intervention: 4 g sucralfate daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30132821

Group type: EXPERIMENTAL
Intervention: Neostigmine 2.5 mg with glycopyrrolate 450 μg (first dose)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Neostigmine 2.5 mg with glycopyrrolate (second dose)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Neostigmine 2.5 mg with glycopyrrolate (first dose)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (normal saline 0.9%)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Neostigmine 2.5 mg with glycopyrrolate (first and second doses)
Number of subjects: 21
Study: 28251295

Group type: EXPERIMENTAL
Intervention: Daily pin care (group A)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Every 2 days pin care (group B)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Weekly pin care (group C)
Number of subjects: 135

Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 135
Study: 26690350

Group type: EXPERIMENTAL
Intervention: BMMNC transplantation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 26
Study: 22815282

Group type: EXPERIMENTAL
Intervention: 6° full‐length medially wedged foot orthoses
Number of subjects: 20
Study: 21165642

Group type: EXPERIMENTAL
Intervention: Nutrient ingestion (24 g whey, 4.8 g leucine, 50 g maltodextrin)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non-caloric placebo ingestion
Number of subjects: 8
Study: 19705947

Group type: EXPERIMENTAL
Intervention: Removable Hawley retainer
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bonded retainers
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 17197088

Group type: COMPARATOR
Intervention: Pain-induced changes in plasma beta-endorphin (BE) following acute pain tasks (finger pressure, ischemic, and thermal)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Anger-out
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Anger-in
Number of subjects: 27
Study: 14575732

Group type: EXPERIMENTAL
Intervention: Offspring of parents with bipolar disorder (BD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Offspring of parents with no mental disorder (NMD)
Number of subjects: 20
Study: 11544839

Group type: EXPERIMENTAL
Intervention: Combination of progestins and anticoagulants (500 mg, i.v., for 10 days for AH; 20 days for moderately- and poorly-differentiated cell CAC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Preoperative progestin therapy without anticoagulants
Number of subjects: 120
Study: 9773139

Group type: EXPERIMENTAL
Intervention: Dopexamine (2 micrograms.kg‐1.min‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study: 8162733

Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination (SDD)
Number of subjects: 2210
Study: 3006980

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg b.w. propranolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 29057618

Group type: EXPERIMENTAL
Intervention: bococizumab 0.25 mg/kg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: bococizumab 1 mg/kg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: bococizumab 3 mg/kg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: bococizumab 6 mg/kg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: bococizumab 6 mg/kg (all three doses)
Number of subjects: 135
Study: 26669255

Group type: EXPERIMENTAL
Intervention: Sesame oil Shirodhara (SOS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Warm water Shirodhara (WWS)
Number of subjects: 20
Study: 24810827

Group type: EXPERIMENTAL
Intervention: Abductor shuck (AS) method
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Tranosseous pins with calibrated caliper (TP) method
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Patella electrocardiogram (EKG) leads (PL) method
Number of subjects: 81
Study: 21645982

Group type: EXPERIMENTAL
Intervention: CT enterography (CTE)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MR enterography (MRE)
Number of subjects: 26

Group type: COMPARATOR
Intervention: CTE and MRE
Number of subjects: 26
Study: 20207860

Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study: 18314215

Group type: EXPERIMENTAL
Intervention: 10 mg/kg UDCA
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 20 mg/kg UDCA
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 30 mg/kg UDCA
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: All doses of UDCA
Number of subjects: 31
Study: 17267790

Group type: EXPERIMENTAL
Intervention: Imipramine plus CBT
Number of subjects: 172

Group type: COMPARATOR
Intervention: Imipramine alone
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 15593038

Group type: EXPERIMENTAL
Intervention: High-flux dialysis (Fresenius F60) for 6 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low-flux dialysis (Fresenius F6 HPS) for 6 months
Number of subjects: 48
Study: 10657417

Group type: EXPERIMENTAL
Intervention: Midlife aortic atherosclerosis
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Severity of midlife aortic atherosclerosis
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Late-life aortic atherosclerosis
Number of subjects: 807
Study: 9069479

Group type: EXPERIMENTAL
Intervention: Lewy body dementia
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Parkinson's disease
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 78
Study: 8410645

Group type: EXPERIMENTAL
Intervention: Experimental oral intervention (taste, smell, and oral tactile stimulation)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Traditional tactile stimulation (moderate shaking applied to the infant's leg)
Number of subjects: 14
Study: 3102387

Group type: EXPERIMENTAL
Intervention: Single 800 mg dose of ofloxacin (32 patients)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Single 400 mg dose of ofloxacin (55 patients)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Twice a day dose of 600 mg ofloxacin (34 patients)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 400 mg ofloxacin twice a day for 7-10 days (19 patients with urinary tract infection)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 400 mg ofloxacin twice a day for 7-10 days (8 patients with enteric fever)
Number of subjects: 121
Study: 30602397

Group type: EXPERIMENTAL
Intervention: Focus group discussions on the conceptualization of depression
Number of subjects: 81
Study: 28040692

Group type: EXPERIMENTAL
Intervention: BRAF V600E mutations in MSS patients
Number of subjects: 4411

Group type: EXPERIMENTAL
Intervention: KRAS codon 12 alterations and p.G13D mutations in MSS patients
Number of subjects: 4411

Group type: EXPERIMENTAL
Intervention: BRAF mutations in MSS patients
Number of subjects: 4411

Group type: EXPERIMENTAL
Intervention: KRAS mutations in MSS patients
Number of subjects: 4411

Group type: COMPARATOR
Intervention: No mutations in MSI patients
Number of subjects: 4411
Study: 25874951

Group type: EXPERIMENTAL
Intervention: Rebamipide 300 mg three times daily for 8 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 38
Study: 23987126

Group type: EXPERIMENTAL
Intervention: Intervention discussing evidence about choice disability with local HIV prevention services
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Intervention discussing an eight-episode audio-docudrama with community groups
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Support groups for women aged 18 to 25 years to build self-esteem and life skills
Number of subjects: 77

Group type: COMPARATOR
Intervention: Existing prevention efforts (control group)
Number of subjects: 77
Study: 21407110

Group type: EXPERIMENTAL
Intervention: 1 ng/mL Escherichia coli lipopolysaccharide (LPS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 5 ng/mL Escherichia coli lipopolysaccharide (LPS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (HCs)
Number of subjects: 35
Study: 19216298

Group type: EXPERIMENTAL
Intervention: Topical skin protectant lotion (IB1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 16753013

Group type: EXPERIMENTAL
Intervention: School curriculum-based exercise program (40 minutes per school day, 200 minutes/week)
Number of subjects: 99
Study: 15198188

Group type: COMPARATOR
Intervention: Placebo treatment for 7 days (288 patients)
Number of subjects: 1143
Study: 11728541

Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan
Number of subjects: 24089

Group type: EXPERIMENTAL
Intervention: 10 mg rizatriptan
Number of subjects: 24089

Group type: EXPERIMENTAL
Intervention: 80 mg eletriptan
Number of subjects: 24089

Group type: EXPERIMENTAL
Intervention: 12.5 mg almotriptan
Number of subjects: 24089

Group type: EXPERIMENTAL
Intervention: 2.5 mg naratriptan
Number of subjects: 24089

Group type: EXPERIMENTAL
Intervention: 20 mg eletriptan
Number of subjects: 24089

Group type: EXPERIMENTAL
Intervention: 2.5 mg and 5 mg zolmitriptan
Number of subjects: 24089

Group type: EXPERIMENTAL
Intervention: 40 mg eletriptan
Number of subjects: 24089

Group type: EXPERIMENTAL
Intervention: 5 mg rizatriptan
Number of subjects: 24089

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24089
Study: 9296454

Group type: EXPERIMENTAL
Intervention: Antioxidants (n‐acetylcysteine 150 mg/kg for 30 min then 20 mg/kg/h plus bolus doses of 1 g ascorbic acid and 400 mg alpha‐tocopherol)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 30

Group type: COMPARATOR
Intervention: 5% dextrose (control)
Number of subjects: 30
Study: 8420296

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Combination therapy (Pravastatin + Gemfibrozil)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 3749299

Group type: EXPERIMENTAL
Intervention: Caffeine (20 to 160 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caffeine (160 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine (various doses including 0, 20, 40, 80, 160 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine (80 mg)
Number of subjects: 0
Study: 31426272

Group type: EXPERIMENTAL
Intervention: SEDDS-CBD (25 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: MCT-CBD
Number of subjects: 16
Study: 28135883

Group type: EXPERIMENTAL
Intervention: Monophasic hyaluronic acid filler
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Biphasic hyaluronic acid filler
Number of subjects: 10

Group type: COMPARATOR
Intervention: MRI assessment
Number of subjects: 10
Study: 26735229

Group type: EXPERIMENTAL
Intervention: Voluntary Isocapnic Hyperventilatory Training (VIHT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PVIHT)
Number of subjects: 0
Study: 25439055

Group type: EXPERIMENTAL
Intervention: Pre-emptive early interventions (PEI) including skill training for parents of younger children and courses in emotional well-being skills based on cognitive behavioural therapy for older children and youth.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-emptive early interventions (PEI)
Number of subjects: 0
Study: 23311248

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with propofol and midazolam
Number of subjects: 60

Group type: COMPARATOR
Intervention: General balanced anesthesia (GBA) with midazolam, thiopenton, nitrous oxide, and O2
Number of subjects: 60
Study: 19220845

Group type: EXPERIMENTAL
Intervention: Straumann implants
Number of subjects: 28

Group type: COMPARATOR
Intervention: Brånemark implants
Number of subjects: 28
Study: 18569900

Group type: EXPERIMENTAL
Intervention: Brief office intervention (BOI) consisting of four weekly individual sessions lasting 10 to 40 minutes each, incorporating motivational interviewing and cognitive-behavioral techniques.
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Brief office intervention (BOI)
Number of subjects: 69
Study: 15748685

Group type: EXPERIMENTAL
Intervention: Theory of Planned Behaviour (TPB) questionnaire
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TPB questionnaire + implementation intention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 12480588

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) in combination with radiotherapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Radiotherapy only
Number of subjects: 92
Study: 9792192

Group type: EXPERIMENTAL
Intervention: Low BMI (LBMI) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal BMI (NBMI) group
Number of subjects: 0
Study: 7614107

Group type: EXPERIMENTAL
Intervention: Liquid lactulose
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Crystallized lactulose
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Crystallized lactitol
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study: 2533154

Group type: EXPERIMENTAL
Intervention: Ovarian ablation (surgical oophorectomy or irradiation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Depot Zoladex
Number of subjects: 0
Study: 920252

Group type: EXPERIMENTAL
Intervention: Thermography
Number of subjects: 51

Group type: COMPARATOR
Intervention: Phlebography
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Fibrin-fibrinogen degradation products (FDP) assay
Number of subjects: 51
Study: 31713129

Group type: EXPERIMENTAL
Intervention: Synbiotic pomegranate juice (SPJ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synbiotic beverage (SB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo beverage (PB)
Number of subjects: 0
Study: 30985702

Group type: EXPERIMENTAL
Intervention: Short version of the Inventory of Quality for Early Intervention Centers (IQEIC)
Number of subjects: 887
Study: 28696503

Group type: EXPERIMENTAL
Intervention: P. pratense allergoid (1800 TU, 6000 TU, 18000 TU)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 6-grass pollen allergoid (6000 TU)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard-dose P. pratense allergoid (6000 TU)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: High-dose P. pratense allergoid (18000 TU)
Number of subjects: 102
Study: 25681064

Group type: EXPERIMENTAL
Intervention: SSM‐VIMT (malaria transmission blocking vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0